Theodore T. Lee, JD; Daniel H. Solomon, MD, MPH; Aaron S. Kesselheim, MD, JD, MPH
Acknowledgment: The authors thank Dr. Ameet Sarpatwari, JD, PhD, for his comments on an earlier draft.
Financial Support: Dr. Kesselheim's work is funded by the Open Society Foundations, as well as by Arnold Ventures, the Engelberg Foundation, and the Harvard-MIT Center for Regulatory Science.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-1218.
Corresponding Author: Aaron S. Kesselheim, MD, JD, MPH, Division of Pharmacoepidemiology & Pharmacoeconomics, 1620 Tremont Street, Suite 3030, Boston, MA 02120; e-mail, email@example.com.
Current Author Addresses: Mr. Lee: 1114 Avenue of the Americas, Floor 43, New York, NY 10036.
Dr. Solomon: Division of Rheumatology, Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA 02115.
Dr. Kesselheim: Division of Pharmacoepidemiology & Pharmacoeconomics, 1620 Tremont Street, Suite 3030, Boston, MA 02120.
Author Contributions: Conception and design: T.T. Lee, D.H. Solomon, A.S. Kesselheim.
Drafting of the article: T.T. Lee.
Critical revision of the article for important intellectual content: T.T. Lee, D.H. Solomon, A.S. Kesselheim.
Final approval of the article: T.T. Lee, D.H. Solomon, A.S. Kesselheim.
Obtaining of funding: A.S. Kesselheim.
Lee TT, Solomon DH, Kesselheim AS. Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act. Ann Intern Med. 2019;171:578–579. [Epub ahead of print 1 October 2019]. doi: https://doi.org/10.7326/M19-1218
Download citation file:
Published: Ann Intern Med. 2019;171(8):578-579.
Published at www.annals.org on 1 October 2019
Acute Coronary Syndromes, Cardiology, Coagulopathies, Coronary Heart Disease, Coronary Risk Factors.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use